摘要
Alzheimer’s disease(AD)is a prominent form of dementia,characterized by aggregation of the amyloidβ-peptide(Aβ)plaques and neurofibrillary tangles,loss of synapses and neurons,and degeneration of cognitive functions.Currently,although a variety of medications can relieve some of the symptoms,there is no cure for AD.Recent breakthroughs in the stem cell field provide promising strategies for AD treatment.Stem cells including embryonic stem cells(ESCs),neural stem cells(NSCs),mesenchymal stem cells(MSCs),and induced pluripotent stem cells(iPSCs)are potentials for AD treatment.However,the limitation of cell sources,safety issues,and ethical issues restrict their applications in AD.Recently,the direct reprogramming of induced neural progenitor cells(iNPCs)has shed light on the treatment of AD.In this review,we will discuss the latest progress,challenges,and potential applications of direct reprogramming in AD treatment.
基金
by research grants by National Basic Research Program of China(973 Program Grant No.2014CB965001)
National Natural Science Foundation of China(#81271419)
Innovative Research Groups of the National Natural Science Foundation of China(#81221001)
Joint Research Fund for Overseas Chinese,Hong Kong and Macao Young Scientists of the National Natural Science Foundation of China(#81329002)
National Institutes of Health:R01 NS 41858–01,R01 NS 061642–01,P20 RR15635-01,the State of Nebraska,DHHS-LB606 Stem Cell 2009–10(JZ),LB606 Stem Cell-2010-10(CT).Julie Ditter,Lenal Bottoms,Johna Belling,Jaclyn Ostronic and Robin Taylor provided outstanding administrative and secretarial support.
